Updated Survival Data from FLAURA2 and MARIPOSA Trials Reshape Treatment Selection in EGFR-Mutated Advanced NSCLC
核心洞察
Updated overall survival data from the FLAURA2 trial show osimertinib plus chemotherapy achieved a median OS of 47.5 months versus 37.6 months with osimertinib monotherapy, with a favorable hazard ratio of 0.77.
The MARIPOSA trial demonstrated that amivantamab plus lazertinib provided a significant OS benefit compared to osimertinib monotherapy, though interpretation is complicated by lack of crossover design.
Treatment selection remains individualized, with clinicians increasingly seeking reasons to de-escalate to single-agent osimertinib based on patient performance status, quality of life goals, and toxicity considerations.
Updated overall survival findings from pivotal phase 3 trials are reshaping treatment decisions for patients with EGFR-mutated advanced non-small cell lung cancer (搜索) (NSCLC (搜索)), as combination therapies demonstrate meaningful survival advantages over single-agent osimertinib while raising new questions about optimal treatment sequencing and patient selection.
FLAURA2 Delivers Sustained Survival Benefit
Final overall survival data from the phase 3 FLAURA2 trial presented at the 2025 World Conference on Lung Cancer showed that osimertinib plus platinum-based chemotherapy (搜索) significantly outperformed osimertinib monotherapy. At a median follow-up of approximately 51 months, the combination achieved a median OS of 47.5 months (95% CI, 41.0-not calculable) compared to 37.6 months (95% CI, 33.2-43.2) with monotherapy (HR, 0.77; 95% CI, 0.61-0.96; P = .02).
The 3-year OS rates were 63% versus 51%, respectively, while 4-year OS rates reached 49% versus 41%. Notably, the survival curves maintained separation longer than anticipated, with panelists expressing surprise at the durability of benefit.
"The HR [for OS] in FLAURA2 was better than I thought," noted Jeffrey P. Ward, MD, PhD, from Washington University School of Medicine. "The crossover rate was pretty high, but I thought [the curve] was going to narrow more, given the amount of chemotherapy patients received later. This raises many mechanistic scientific questions about what is occurring early on."
The FDA approved osimertinib in combination with platinum-based chemotherapy (搜索) in February 2024 based on these FLAURA2 findings for patients with locally advanced or metastatic EGFR (搜索)-mutated NSCLC (搜索) harboring exon 19 deletions or exon 21 L858R substitutions.
MARIPOSA Data Support Alternative Combination Strategy
The MARIPOSA trial provided evidence for amivantamab plus lazertinib as another frontline combination option, leading to FDA approval in August 2024. Updated data published in The New England Journal of Medicine showed a significant OS benefit, with median OS not estimable (95% CI, 42.9 months-NE) for amivantamab plus lazertinib versus 36.7 months (95% CI, 33.4-41.0) for osimertinib monotherapy (HR, 0.75; 95% CI, 0.61-0.92; P = .005) at a median follow-up of 37.8 months.
However, the lack of crossover in MARIPOSA created interpretive challenges. "My interpretation of these curves is that we do not know what survival advantage amivantamab plus lazertinib offers over osimertinib in the current environment [without planned crossover]," Ward stated.
The trial's mandated brain magnetic resonance imaging provided higher-quality central nervous system data, with MARIPOSA demonstrating that amivantamab plus lazertinib significantly improved intracranial progression-free survival compared to osimertinib monotherapy, effectively doubling outcomes in patients with baseline brain metastases (搜索).
Treatment Selection Becomes More Nuanced
Despite the efficacy advantages of combination therapy, treatment selection has evolved toward more individualized decision-making. Clinicians report a shift from seeking reasons to intensify treatment to identifying appropriate candidates for de-escalation to single-agent osimertinib.
"Two years ago, we were searching for reasons to intensify treatment for patients. Now, it's almost the opposite; I'm searching for reasons not to intensify and to de-escalate to single-agent osimertinib," explained Eric K. Singhi, MD, from MD Anderson Cancer Center. "The treatment of these patients is based not so much on age, but on their performance status, goals, and quality of life."
Current real-world usage patterns reflect this individualized approach. Kaushal Parikh, MBBS, from Mayo Clinic reported that "25% to 30% of my patients receive single-agent osimertinib even now, while another 65% to 70% receive chemotherapy plus osimertinib."
Safety Considerations Influence Treatment Choice
A patient-level toxicity comparison presented at the 2025 WCLC revealed higher rates of grade 3 or higher adverse events with amivantamab plus lazertinib versus osimertinib plus chemotherapy (OR, 1.68; 95% CI, 1.21-2.34; P = .0022), as well as higher rates of serious adverse events (OR, 1.56; 95% CI, 1.15-2.13; P = .0052). Treatment discontinuation rates due to adverse events were comparable between regimens.
Dermatologic adverse events associated with amivantamab remain a practical concern. Data from the phase 2 COCOON trial showed that patients receiving an enhanced prophylactic regimen experienced significantly lower incidence of grade 2 or higher dermatologic adverse events during the first 12 weeks compared to standard management (42% vs 75%; OR, 0.24; 95% CI, 0.13-0.45; P < .0001).
Second-Line Treatment Options Emerge
Following progression on frontline osimertinib, two main strategies have emerged. The MARIPOSA-2 trial showed that amivantamab plus chemotherapy provided a numerical OS benefit compared to chemotherapy alone (HR, 0.73; 95% CI, 0.54-0.99; P = .039), with 18-month OS rates of 50% versus 40%, respectively.
Alternatively, the COMPEL trial demonstrated that continuing osimertinib with platinum-based chemotherapy (搜索) after progression improved outcomes, achieving a median progression-free survival of 8.4 months compared to 4.4 months with placebo plus chemotherapy (HR, 0.43; 95% CI, 0.27-0.70).
"The fight was between MARIPOSA and FLAURA2," concluded Sonam Puri, MD, from Moffitt Cancer Center. "Now, the fight is going to be between MARIPOSA-2 and COMPEL."
These evolving data continue to inform treatment selection in EGFR (搜索)-mutated advanced NSCLC (搜索), with combination therapies demonstrating clear survival benefits while highlighting the importance of individualized treatment decisions based on patient factors, toxicity profiles, and quality of life considerations.